Europe GLP-1 Agonist Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers GLP-1 Agonists Brands & Drug List in Europe and the market is segmented into drugs (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), brands (Byetta, Bydureon, Victoza, Trulicity, Lyxumia, and Ozempic) and Geography (Germany, Spain, Italy, France, United Kingdom, Russia, and Rest of Europe). The market provides the value (in USD million) for the above-mentioned segments.

Europe GLP-1 Agonist Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Size

View Global Report
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 4.17 Billion
Market Size (2030) USD 5.56 Billion
CAGR (2025 - 2030) 5.90 %
Market Concentration High

Major Players

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Analysis

The Europe Glucagon-Like Peptide-1 Agonists Market size is estimated at USD 4.17 billion in 2025, and is expected to reach USD 5.56 billion by 2030, at a CAGR of 5.9% during the forecast period (2025-2030).

mainly as a result of new drug launches. Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway. Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry Overview

The Europe GLP-1 market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc., holding a presence in the region.

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Leaders

  1. Novo Nordisk

  2. AstraZeneca

  3. Eli lilly and Company

  4. Sanofi

  5. Pfizer

  6. *Disclaimer: Major Players sorted in no particular order
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market News

  • April 2023: Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes. Amphastar expects to provide dedicated commercial investment for BAQSIMI with the goal of enabling more people on insulin to be prepared with a glucagon rescue treatment for severe hypoglycemia.
  • March 2023: NHS approved Wegovy, a weight loss injection also known as semaglutide. Wegovy mimics the hormone glucagon-like peptide-1 (GLP-1) and suppresses appetite.

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Exenatide
    • 5.1.1.1 Byetta
    • 5.1.1.2 Bydureon
    • 5.1.2 Liraglutide
    • 5.1.2.1 Victoza
    • 5.1.3 Lixisenatide
    • 5.1.3.1 Lyxumia
    • 5.1.4 Dulaglutide
    • 5.1.4.1 Trulicity
    • 5.1.5 Semaglutide
    • 5.1.5.1 Ozempic
  • 5.2 Geography
    • 5.2.1 Germany
    • 5.2.2 Spain
    • 5.2.3 Italy
    • 5.2.4 France
    • 5.2.5 United Kingdom
    • 5.2.6 Russia
    • 5.2.7 Rest of Europe

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 AstraZeneca
    • 7.1.3 Eli Lilly and Company
    • 7.1.4 Sanofi
    • 7.1.5 Biocon
    • 7.1.6 Novartis
    • 7.1.6.1 Other Key Players
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Novo Nordisk
    • 7.2.2 AstraZeneca
    • 7.2.3 Eli Lilly and Company

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry Segmentation

GLP-1 receptor agonists are a non-insulin medication used in combination with diet and exercise to help treat type 2 diabetes. The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), brands (Byetta, Bydureon, Victoza, Trulicity, Lyxumia, and Ozempic) and Geography (Germany, Spain, Italy, France, United Kingdom, Russia, and Rest of Europe). The report offers the value (in USD million) and volume (in Units million) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Drug Exenatide Byetta
Bydureon
Liraglutide Victoza
Lixisenatide Lyxumia
Dulaglutide Trulicity
Semaglutide Ozempic
Geography Germany
Spain
Italy
France
United Kingdom
Russia
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Research FAQs

How big is the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 4.17 billion in 2025 and grow at a CAGR of 5.90% to reach USD 5.56 billion by 2030.

What is the current Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size?

In 2025, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 4.17 billion.

Who are the key players in Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

Novo Nordisk, AstraZeneca, Eli lilly and Company, Sanofi and Pfizer are the major companies operating in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market.

What years does this Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market cover, and what was the market size in 2024?

In 2024, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size was estimated at USD 3.92 billion. The report covers the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Europe GLP-1 Agonists Industry Report

Statistics for the 2025 Europe Glucagon-Like Peptide-1 (GLP-1) Agonists market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Glucagon-Like Peptide-1 (GLP-1) Agonists analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Europe GLP-1 Agonists Market Report Snapshots